|
gptkbp:instanceOf
|
gptkb:receptor_tyrosine_kinase
gptkb:drug
|
|
gptkbp:approvedBy
|
gptkb:FDA
gptkb:EMA
2014
|
|
gptkbp:ATCCode
|
L01XE31
|
|
gptkbp:brand
|
gptkb:Ofev
|
|
gptkbp:CASNumber
|
656247-17-5
|
|
gptkbp:contraindication
|
severe hepatic impairment
hypersensitivity to nintedanib
|
|
gptkbp:developedBy
|
gptkb:Boehringer_Ingelheim
|
|
gptkbp:drugClass
|
gptkb:antineoplastic_agent
|
|
gptkbp:eliminationHalfLife
|
9.5 hours
|
|
gptkbp:excretion
|
urine
feces
|
|
gptkbp:hasMolecularFormula
|
C31H33N5O4
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
inhibits multiple receptor tyrosine kinases
blocks VEGFR, FGFR, and PDGFR
|
|
gptkbp:metabolism
|
hepatic
|
|
gptkbp:molecularWeight
|
539.6 g/mol
|
|
gptkbp:pregnancyCategory
|
D (US)
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
nausea
vomiting
diarrhea
liver enzyme elevation
|
|
gptkbp:usedFor
|
gptkb:non-small_cell_lung_cancer
idiopathic pulmonary fibrosis
systemic sclerosis-associated interstitial lung disease
|
|
gptkbp:bfsParent
|
gptkb:protein_tyrosine_kinases
|
|
gptkbp:bfsLayer
|
7
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
nintedanib
|